Highlights From the American Diabetes Association Scientific Session 2023 episode artwork

EPISODE · Jul 12, 2023 · 12 MIN

Highlights From the American Diabetes Association Scientific Session 2023

from JAMA Medical News

Data on a new crop of hormone analogues for weight loss—including an oral version of semaglutide and the triple agent retatrutide—were recently presented at the American Diabetes Association's annual Scientific Sessions. Robert Gabbay, MD, PhD, the ADA's chief scientific and medical officer, speaks with JAMA's Jennifer Abbasi about this and other clinical data presented at the meeting. Related Content: New Weight Loss Drugs Make Headlines at Diabetes Meeting

NOW PLAYING

Highlights From the American Diabetes Association Scientific Session 2023

0:00 12:36

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of JAMA Medical News?

This episode is 12 minutes long.

When was this JAMA Medical News episode published?

This episode was published on July 12, 2023.

What is this episode about?

Data on a new crop of hormone analogues for weight loss—including an oral version of semaglutide and the triple agent retatrutide—were recently presented at the American Diabetes Association's annual Scientific Sessions. Robert Gabbay, MD, PhD, the...

Can I download this JAMA Medical News episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!